Company Overview of SpePharm Holding B.V.
SpePharm Holding B.V., a specialty pharmaceutical company, engages in acquiring, registering, and marketing specialty medicines, essentially for the hospital market. The company focuses on oncology and hematology, critical, and supportive care. It offers Loramyc, a muco-adhesive buccal tablet, is an anti-infective for local oral treatment; and MuGard, a ready-to-use mucoadhesive oral rinse, for the management of oral mucositis that may be caused by radiotherapy and/or chemotherapy. The company offers its products in European Union, Switzerland, Norway, and Iceland. SpePharm Holding B.V. was founded in 2006 and is based in Amsterdam, the Netherlands. It has operations in Milan, Italy; Munich,...
Amsterdam, 1043 GR
Founded in 2006
Key Executives for SpePharm Holding B.V.
Chief Executive Officer and Managing Director
Vice President of Commercial Operations
Director and President of SpePharm SAS (France)
Compensation as of Fiscal Year 2014.
SpePharm Holding B.V. Key Developments
Norgine B.V. and SpePharm Holding B.V. Enter Into Joint Venture
Dec 17 12
Norgine B.V. and SpePharm Holding B.V. announced that they have concluded a broad collaboration agreement under which the two companies have invested in a 50:50 joint venture, SpePharm AG, which has acquired the entire product portfolio of SpePharm Holding, including Savene, MuGard, Xerotin, PROther and the Dantrium brands. The new joint venture will commercialise this entire product portfolio through Norgine’s pharmaceutical infrastructure, which spans all of the major markets of Europe. SpePharm AG will seek to acquire further hospital based products which will also be sold through Norgine’s commercial infrastructure. Financial terms were not disclosed.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries